Determined to work together more, the two set their sights on neurodegenerative disease because they believed they were in a unique position to advance research in that area. In that area, we'd be more powerful as a team than as individuals working on separate problems. Their team of researchers there publishes about 35 papers a year. Their current research focuses on identifying early indicators of Alzheimer's disease and using them to measure responses to various therapies. There might be drugs on the shelves of pharmaceutical companies today that could delay the onset of Alzheimer's for 10 years.
Early detection is critical to seeing the efficacy of therapies.
This grant intends to identify early markers of Alzheimer's disease and to use these markers to follow the response to therapy. This is a critical piece of science to have nailed down because it allows us to accelerate the pace of drug screening, clinical trials, and the sorting out of existing drugs to see which will have the greatest benefit for Alzheimer patients. Inc. All rights reserved.